Get 50% OFF This Monsoon!
Par Drugs & Chemicals
No Data Available
No Stocks
Unlock Smart Score
See Detailed Analysis & Insights
Unlock Insights
See Detailed Analysis & Insights
No Research Report
ROE
Avg ROE (3 Yrs) : NaN%
ROCE
Avg ROCE (3 Yrs) : NaN%
ROA
Avg ROA (3 Yrs) : NaN%
NPM
Avg NPM (3 Yrs) : NaN%
No Data Available
Unlock Management Data
See Detailed Analysis & Insights
Par Drugs and Chemicals Limited was originally incorporated as a private limited company with the name 'Par Drugs and Chemicals Private Limited' at Bhavnagar, Gujarat. On 26 February 1999. Subsequently, the company was converted into a public limited company pursuant to special resolution passed by the members in extra-ordinary general meeting of the company held on October 24, 2018 and the name of the company was changed to 'Par Drugs and Chemicals Limited' on 5 November 2018.
Vallabhbhai Savani and Sarita Savani were initial subscribers to the Memorandum of Association of the company. The Promoters of the company are Jignesh Vallabhbhai Savani and Falgun Vallabhbhai Savani. The Jignesh Vallabhbhai Savani and Falgun Vallabhbhai Savani have first shares on 19, 2006 through allotment of shares by company.
The Company is engaged in the development and manufacture of Active Pharma ingredients ('APIs') for the domestic market as well as for exports to international markets. APIs, also known as 'bulk drugs' or 'bulk actives' are the principal ingredients used in making finished dosages in the form of capsules, tablets, liquid, or other forms of dosage, with the addition of other APIs or inactive ingredients. The Company produce various range of Antacid Molecules which are available in the market and are in great demand.
The Company currently own and operate two manufacturing facilities at Bhavnagar and Ankleshwar in the Gujarat. It currently have three manufacturing blocks at Bhavnagar facility for different products. The Bhavnagar facility certified by food & drugs control administration. During the year 2011, the company has added two manufacturing block out of three at Chitra, Bhavnagar facility. One is dedicated facility for its main API and another one is for Fine Chemicals.
The Product portfolio presently comprises 12 APIs and 6 Fine Chemicals which are marketed domestically and exported. The Company supplies its products to approximately 16 countries, including both direct and indirect exports. The Key customers include Essential Drugs Company Limited, Taurus Chemicals (P) Limited, Pfizer Limited, United Phosphorus Limited(Samba Jammu Unit), Shiv Silica Private Limited.
Par Drugs & Chemicals share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.
Market capitalization of Par Drugs & Chemicals indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Par Drugs & Chemicals is valued compared to its competitors.
Par Drugs & Chemicals PE ratio helps investors understand what is the market value of each stock compared to Par Drugs & Chemicals 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.
The PEG ratio of Par Drugs & Chemicals evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.
Return on Equity (ROE) measures how effectively Par Drugs & Chemicals generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.
Return on Capital Employed (ROCE) evaluates the profitability of Par Drugs & Chemicals in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.
Total debt of Par Drugs & Chemicals shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.
The Debt-to-Equity (DE) ratio of Par Drugs & Chemicals compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.
CAGR shows the consistent growth rate of Par Drugs & Chemicals over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.
Technical analysis of Par Drugs & Chemicals helps investors get an insight into when they can enter or exit the stock. Key components of Par Drugs & Chemicals Technical Analysis include:
There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.
There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Par Drugs & Chemicals shares often struggle to rise above due to selling pressure.
Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Par Drugs & Chemicals ’s financial health and profitability.
Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.
Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.
The financials of Par Drugs & Chemicals provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.
The profit and loss statement of Par Drugs & Chemicals highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Par Drugs & Chemicals .
The balance sheet presents a snapshot of Par Drugs & Chemicals ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.
Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.
Download the App